全身性硬化症(強皮症)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0691
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年1月14日
◆ページ数:374
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Systemic Sclerosis (Scleroderma) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) – Pipeline Review, H1 2020, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 17, 11, 32 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Systemic Sclerosis (Scleroderma) – Overview
Systemic Sclerosis (Scleroderma) – Therapeutics Development
Systemic Sclerosis (Scleroderma) – Therapeutics Assessment
Systemic Sclerosis (Scleroderma) – Companies Involved in Therapeutics Development
Systemic Sclerosis (Scleroderma) – Drug Profiles
Systemic Sclerosis (Scleroderma) – Dormant Projects
Systemic Sclerosis (Scleroderma) – Discontinued Products
Systemic Sclerosis (Scleroderma) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Systemic Sclerosis (Scleroderma) - Pipeline by Accuitis Pharmaceuticals Inc, H1 2020
Systemic Sclerosis (Scleroderma) - Pipeline by AKL Research and Development Ltd, H1 2020
Systemic Sclerosis (Scleroderma) - Dormant Projects, H1 2020
Systemic Sclerosis (Scleroderma) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Systemic Sclerosis (Scleroderma) - Dormant Projects, H1 2020 (Contd..2), H1 2020
Systemic Sclerosis (Scleroderma) - Discontinued Products, H1 2020

【掲載企業】

Accuitis Pharmaceuticals Inc
AKL Research and Development Ltd
Allysta Pharmaceuticals Inc
Amgen Inc
AnaMar AB
Anima Biotech Inc
arGentis Pharmaceuticals LLC
Aryogen Pharmed Co
AstraZeneca Plc
Atlantic Healthcare Plc
Biogen Inc
Biomendics LLC
Blade Therapeutics Inc
BriaCell Therapeutics Corp
Bristol-Myers Squibb Co
Cantargia AB
Capella Bioscience Ltd
Castle Creek Pharmaceuticals LLC
ChemomAb Ltd
Civi Biopharma Inc
Cleveland Diabetes Care Inc
Corbus Pharmaceuticals Inc
CSL Ltd
Cumberland Pharmaceuticals Inc
Cureveda LLC
D&D Pharmatech Co Ltd
Daewoong Pharmaceutical Co Ltd
Emerald Health Sciences Inc
Ergon Pharmaceuticals LLC
FBM Therapeutics LLC
Forbius
Fresenius SE & Co KGaA
Galapagos NV
GenKyoTex SA
Gesynta Pharma AB
Gilead Sciences Inc
GlaxoSmithKline Plc
GNI Group Ltd
H. Lundbeck AS
iBio Inc
Ichnos Sciences Inc
Johnson & Johnson
Kadmon Corp LLC
Leadiant Biosciences Inc
Liminal BioSciences Inc
Link Genomics Inc
MDI Therapeutics Inc
medac GmbH
Opsidio LLC
Panorama Research Inc
Patagonia Pharmaceuticals LLC
PDX Pharmaceuticals LLC
Peptinov SAS
Pfizer Inc
PharmAkea Therapeutics Inc
Resolys Bio Inc
Ribomic Inc
Riptide Bioscience Inc
Samumed LLC
Sanofi
Seattle Genetics Inc
Signablok Inc
Stemline Therapeutics Inc
StemMed Ltd
Takeda Pharmaceutical Co Ltd
Tvardi Therapeutics Inc
Unity Biotechnology Inc
Vicore Pharma AB
Viela Bio Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[全身性硬化症(強皮症)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆